英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

zestful    音标拼音: [z'ɛstfəl]
a. 有风味的,有风趣的,有热情的

有风味的,有风趣的,有热情的

zestful
adj 1: marked by spirited enjoyment [synonym: {zestful}, {yeasty},
{zesty}, {barmy}]

zestful \zest"ful\ (z[e^]st"f[.u]l), adj.
Marked by spirited enjoyment.

Syn: yeasty, zesty.
[WordNet 1.5]

103 Moby Thesaurus words for "zestful":
active, acute, aggressive, agog, alacritous, all agog, animated,
antic, anxious, avid, bracing, breathless, brisk, burning,
bursting to, capersome, cheering, coltish, cordial, crisp, crispy,
curried, desirous, dynamic, eager, energetic, energizing,
enterprising, enthusiastic, exhilarating, exuberant, forceful,
forcible, forward, fresh, frisky, frolicsome, full of beans,
full of life, full of pep, gamesome, gay, go-go, hearty,
high-seasoned, hot, hot as pepper, impatient, impetuous, incisive,
intense, invigorating, keen, kinetic, lively, living, lusty,
mettlesome, nippy, panting, peppery, peppy, playful, prompt, quick,
racy, raring to, ready, ready and willing, refreshful, refreshing,
regaling, robust, rollicking, rollicksome, rompish, rousing,
seasoned, skittish, smacking, snappy, spanking, spiced, spicy,
spirited, sportive, sprightly, stimulating, strenuous, strong,
take-charge, take-over, tangy, tonic, trenchant, vibrant, vigorous,
vital, vivacious, vivid, with a kick, zesty, zippy


请选择你想看的字典辞典：
单词字典翻译
zestful查看　zestful　在百度字典中的解释百度英翻中〔查看〕
zestful查看　zestful　在Google字典中的解释Google英翻中〔查看〕
zestful查看　zestful　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • FDA approves cemiplimab-rwlc for adjuvant treatment of . . .
    On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc ) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma
  • Libtayo (cemiplimab-rwlc) FDA Approval History - Drugs. com
    Libtayo FDA Approval History Last updated by Judith Stewart, BPharm on Oct 9, 2025 FDA Approved: Yes (First approved September 28, 2018) Brand name: Libtayo Generic name: cemiplimab-rwlc Dosage form: Injection Company: Sanofi Treatment for: Squamous Cell Carcinoma, Basal Cell Carcinoma, Non Small Cell Lung Cancer Libtayo (cemiplimab-rwlc) is a programmed death receptor-1 (PD-1) blocking
  • LIBTAYO® (cemiplimab-rwlc) | Official HCP Website
    LIBTAYO® (cemiplimab-rwlc) is a prescription medicine indicated for the treatment of adult patients with advanced NSCLC, CSCC, BCC, and as an adjuvant treatment for high-risk CSCC See Important Safety full Prescribing Information
  • FDA Approves Libtayo for Adjuvant Treatment of High-Risk CSCC
    Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo The Food and Drug Administration (FDA) has approved Libtayo ® (cemiplimab-rwlc) for the
  • FDA Approves Cemiplimab as Adjuvant Immunotherapy for High . . .
    Last week, Regeneron announced the U S Food and Drug Administration (FDA) approval of cemiplimab-rwlc (Libtayo) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC), particularly in those with a high risk of recurrence after surgery and radiation 1 The PD-1 inhibitor was evaluated under priority review
  • FDA approves Regenerons Libtayo for high-risk CSCC
    The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ fully human monoclonal antibody Libtayo (cemiplimab-rwlc) as an adjuvant therapy for adults with cutaneous squamous cell carcinoma (CSCC) The approval is intended for patients who face an increased risk of the disease returning after surgery and radiation
  • FDA approves Libtayo as immunotherapy for adjuvant treatment . . .
    Regeneron Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for the PD-1 inhibitor Libtayo (cemiplimab-rwlc) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation
  • Libtayo® (cemiplimab-rwlc) Approved in the U. S. as First and . . .
    Libtayo® (cemiplimab-rwlc) Approved in the U S as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
  • LIBTAYO® (cemiplimab-rwlc) in Advanced NSCLC, BCC, CSCC . . .
    Learn about LIBTAYO® (cemiplimab-rwlc) in the treatment of advanced NSCLC, BCC, CSCC, as an adjuvant treatment for high-risk CSCC Review Important Safety Info Full Prescribing Information including Med Guide
  • Cemiplimab Gains FDA Approval for Adjuvant High-Risk CSCC
    The FDA has approved adjuvant cemiplimab (Libtayo) for adults with high-risk cutaneous squamous-cell carcinoma after surgery and radiation





中文字典-英文字典  2005-2009